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DNA methylation and carcinogenesis in digestive
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        The DNA of vertebrates contains tissue specific
patterns of methylated cytosine residues. These
methylation patterns are transmitted by clonal in-
heritance[1] through the strong preferance of mam-
malian DNA (cytosine-5) methyltransferase (DNA-
MTase) for hemimethylated DNA[2], and are estab-
lished     during     early     embryogenesis     and
gametogenesis[3]. Newly replicated DNA lacks this
methylation in the nascent strand. Shortly after the
passage  of  the  replication  fork,  a  maintenance
DNA-MTase methylates CpG dinucleotides on the
newly  synthesized  strand,  thereby  recreating  the
spectrum  of  methyl  groups  that  existed  prior  to
replication.      DNA       methylation     (5-methylcyto-
sine[5-mCyt] content of DNA) plays a considerable role
in  both  normal  development  and  carcinogenesis[4],
but  there  seems  to  be  conflicting  reports  concerning
the role of DNA methylation in carcinogenesis. It
has   been   hypothesized   that   hypomethylation   of
DNA   facilitates   aberrant   gene   expression   in
tumorigenesis[5].   Some   believe   that   hypermethy-
lation of DNA leads to the causative alteration in tu-
morigenesis which involves inactivating tumor sup-
pressor genes and marking chromosome regions for
deletion[6]. Some overlooked the importance of al-
terations in gene expression and thought that muta-
tion played the key role[4]. All these help to achieve
a better understanding of the mechanisms underly-
ing carcinogenesis. We believe that carcinogenesis is
a  multistep/multistage  process  that  occurs  in  ani-
mals[7] with more carcinogenesis than mutagenesis,
and that DNA methylation played multiple roles in
the transformation from a normal cell into a frank
malignancy.
DNA METHYLATION AND CANCER
Mutations which occur at CpG dinucleotides in ver-
tebrate DNA can be attributed to the hydrolytic
deamination of 5-mCyt and are easily recognized be-
cause  of  the  nature  of  base  substitution.  Deamina-
tion of 5-mCyt dinucleotides results in the formation
of thyminephosphoguanosine (TpG). This still does
not account for the high frequency of mutagenesis
observed at CpG sites. Differences in the repairing
efficiencies of promutagenic lesions may be partly
responsible  for  this  discrepancy.  The  guanosine-
thymine    (G-T)    misrepairs    resulting    from
deamination  of  5-mCyt  are  believed  to  be  more
difficult  for  the  cell  to  repair,  as  thymine  is  a
normal component of DNA.
       Mutations   in   the   evolutionarily   conserved
codons of the p53 tumor suppressor gene are com-
mon in diverse types of human cancer. The p53 mu-
tational  spectrum  differs  among  cancers  of  the
colon,  esophagus  and  liver.  Transitions  predomi-
nate  in  colon,  whereas  G:C  to  T:A  transversions
are the most frequent substitutions observed in can-
cers of the liver. Mutations at adeninethymine (A:
T) base pairs are seen more frequently in esophageal
carcinomas than in other solid tumors. Most transi-
tions  in  colorectal  carcinomas  are  at  CpG  dinu-
cleotide mutational hot spots. G-T transversions in
esophageal carcinomas are dispersed among nume-
rous codons[8]. One copy of the short arm of chro-
mosome 17, which harbors the p53 gene, is lost in
many  human  tumors  including  those  of  the  colon
and  rectum.  In  the  colon  carcinomas  75% - 80%
show  a  loss  of  both  p53  alleles,  one  through
deletion, the other through a point mutation. The
point mutations are usually misense, giving rise to
an altered protein[9]. Cytosine-thymine (C-T) tran-
sitions at CpG sites are the most prevalent mutations
found in the p53 tumor suppressor gene in human
colon tumors and in the germline (Li-Fraumeni
syndrome). All of the mutational hot spots are
methylated to 5-mCyt, and it has been hypothesized
that the majority of these mutations are caused by
spontaneous hydrolytic deamination of this base to
thymine[10]. It is estimated that 75%-90% of hepa-
tocellular carcinoma (HCC) cases are attributable to
hepatitis B virus. HBV DNA integrates into HCC
cells at random sites in the genome. It contains the
X gene, which codes for a protein HBX that modu-
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lates the transactivation of many cellular genes and
is a candidate viral oncoprotein. HBX protein binds
with  p53  in  vitro  and  in  vivo[11],  inhibits  p53
sequence-specific DNA binding and transactivation
activities, partially disrupts p53 oligomerization and
prevents  p53  binding  to  transcription-repair  cou-
pling factor ERCC3[12]. HBV infection alone does
not influence the rate of p53 mutation, and aflatox-
in B1 (AFB1) exposure is the most important factor
influencing mutation prevalence. AFB1 plays an eti-
ological role in HCC carcinogenesis and indicates a
synergy  between  HBV  and  AFB1[13].  In  patients
with  liver  tumors  from  geographical  areas  where
both AFB1 and HBV are cancer risk factors, most
mutations are at one nucleotide pair of codon 249[8].
Multiple   gene-tic   alterations   occur   in   gastric
carcinomas,  including  point  mutation  of  the  ras
oncogene and the p53 tumor suppressor gene, ampli-
fication of the c-met, k-sam, and c-erbB-2/neu
genes, and loss of heterozygosity (LOH) of the bcl-
2, APC, and DCC genes. Genetic changes in the
transforming  growth  factor  beta  (TGF-β)  type  II
receptor gene or altered expression of its messenger
RNA[14] occur commonly in gastric cancer cells resis-
tant to growth inhibitory action of TGF-β. Inactiva-
tion of the p53 gene through mutations and the allel-
ic deletion may play an important role in gastric
tumorigenesis. These mutations may cause a confor-
mational change in the p53 protein, resulting in the
loss of p53 suppression of the gastric cell growth
partly through disruption of the association of p53
protein  with  a  cellular  component[15].  Allelic  loss
and mutation of the p53 gene are detected in over
60% of gastric cancers regardless of the histological
type. Several gastric cancer cell lines have shown
p53 gene abnormalities[16]. The c-met gene encoding
the receptor for hepatocyte growth factor (HGF) is
often amplified in advanced gastric cancer, particu-
larly in 39% of scirrhous carcinomas, whereas c-met
amplification is extremely rare in esophageal and
colorectal cancers[17]. The interaction of c-met over-
expressed tumor cells and HGF from activated stro-
mal cells is involved in the morphogenesis and pro-
gression of gastric cancer. The K-sam gene encoding
receptor for keratinocyte growth factor is amplified
preferentially in the poorly differentiated scirrhous
cancer[18]. However, no K-sam amplification is seen
in esophageal and colorectal cancers. In general, K-
sam amplification is independent of c-met amplifi-
cation in scirrhous carcinoma, and c-erbB-2 gene
amplification is detected only in well differentiated
gastric cancer. Moreover, overexpression of c-erbB-
2 is closely correlated with livermetastases. c-Ki-ras
point mutation is observed in 9%-18% of well dif-
ferentiated gastric cancers but not in poorly differ-
entiated ones[19].
MECHANISMS OF DNA METHYLATION IN CAR-
CINOGENESIS
Both general hypomethylation and regional hyper-
methylation coexist in the genome of a wide variety
of human and animal cancers[5,6]. It has been sug-
gested that changes in methylation may not play a
causal role in carcinogenesis and could be conse-
quences of the transformed state of tumor cells and
that C-T transitions brought about by increased ex-
pression of the DNA methyltransferase play the key
role[4]. Beside DNA MTase induced mutations addi-
tional factors appear to be involved in the cancer
process. Cancers originate from a single cell that is
changed dramatically by a series of alterations to the
genome, e.g., mutation and changes in methylation
altered gene expression. Mutagenesis plays a role in
carcinogenesis. Mutated gene must be expressed to
exert an effect.
         It  has  been  suggested  that  reduction  of  DNA
MTase activity would lead to marked hypomethy-
lation which can inhibit tumorigenesis[4,20]. Since
DNA methylation is critical in development and dif-
ferentiation[21] of tumors, it is reasonable to propose
that hypomethylation at an intermediate level plays
a key role in carcinogenesis while excessive hy-
pomethylation may not be compatible with the life
of the affected cells (e.g., owing to massive dere-
gulation of gene expression). By this we mean that
initiated cells may die under the severe conditions of
hypomethylation and would not be available to form
tumors. Thus the fact that inhibition of methylation
may decrease tumor formation does not prove that
excessive DNA MTase activity is the sole mechanism
underlying carcinogenesis.
       There  are  mechanistically  and  theoretically
plausible genotoxic mechanisms that support the
roles  of  both  hypomethylation  and  hypermethy-
lation   of   DNA   (i.e.   epigenetic   changes)   in
carcinogenesis. These involve mainly alterations in
normal gene expression (including tumor suppressor
genes). Altered DNA methylation not only affects
gene expression but also facilitates mutations, as 5-
mCyt  can  deaminate  spontaneously  to  Thymine
(T). This indicates that elevated expression of the
DNA MTase may lead to increased 5-mCyt, and this
can    increase    the    probability    of    C    to    T
transitions[4,22,23]. Moderate DNA-MTase increases
are not merely bystander effects, but could rather
constitute  one  of  the  earliest  and  fundamental
changes of neoplastic development[23]. Hypomethy-
lation of DNA is associated with increased gene
expression[24]. Additionally, a decreased capacity or
fidelity of maintaining the normal methylation sta-
tus of DNA may underlie the sensitivity of some
mouse strains to liver tumorigenesis, in which in-
creased expression of oncogenes appears to be in-
volved by facilitating tumor promotion[5,25,27]. The
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principal  characteristic  of  the  promotion  stage  of
the  carcinogenesis  that  distinguishes  it  from  the
stages of initiation and progression is its operational
reversibility,  i.e.,  clones  of  initiated  cells  regress
when the promoting agent is withdrawn. The pro-
motion stage ends when a lesion attains the capacity
for growth in the absence of a promotion stimulus,
i.e.,   when   it   is   no   longer   reversible   and   can
progress  to  a  frank  malignancy[7].  Hypermethy-
lation of specific regions of DNA has been identified
in  cancer  cells.  For  example,  the  Von  Hippel  Lan-
dau (VHL) tumor suppressor gene is hypermethy-
lated and inactivated in a fraction of renal cell lines
and tumors that did not have mutations in the cod-
ing regions sequenced[6]. Regional chromosomal hy-
permethylation is related to areas believed to con-
tain tumor suppressor genes at various target sites.
This regional hypermethylation in portions of the
genome normally unmethylated may inactivate tu-
mor suppressor genes. The functional significance
would be the same as an inactivating mutation or as
the loss of an allele. Regional hypermethylation of
the retinoblastoma gene appears to inhibit transcrip-
tion of this tumor suppressor genes[26]. Hypermethy-
lation of the 5’CpG island of CDKN2/p16/MTS
(tumor  suppressor  gene  located  on  chromosome
9p21)  is  frequent  in  cell  lines  and  primary  lung
tumors, gliomas and head and neck squamous cell
carcinomas.   Furthermore,   inactivation   through
DNA methylation can occur not only in neoplasms
where deletion is frequent in cell lines (breast, renal
cells) but also in those which are not commonly as-
sociated with loss of p16 through homozygous dele-
tion (colon and prostate). Hypermethylation of the
p16 gene promoter region is a common abnormality
of p16 gene in human cancer[27]. Nearly all acute
leukemias and 50% of chronic leukemias and lym-
phomas show extensive methylation of the estrogen
receptor (ER) gene CpG island[28]. Mutation in the
p53 tumor suppressor gene is believed to occur in
more than half of all solid tumors[29]. Approximate-
ly 24% of point mutations of p53 in human cancers
are C-T transitions at CpG dinucleotides[29]. All of
the mutational hot spots in the p53 gene occurring at
CpG are methylated[30-32], suggesting an involve-
ment of 5-mCyt as an endogenous mutagen. It is im-
portant to not only determine which tumor suppres-
sor genes lie in specific regions and their normal
functions but also demonstrate a causative role, per-
haps by reversing their inactivation. Altered DNA
methylation leads to 5-mCyt which has intrinsic hy-
permutability as compared with C via deamination.
This causes C-T transitions[22]. In the presence of
low levels of S-adenosyl methionine, DNA-MTase
may   be   able   to   form   uracil   leading   to   C-T
transitions[22]. Therefore, the high rate of mutation
at CpG dinucleotides may be due, in part, to DNA-
MTase mediated deamination[4,23], and inhibition of
DNA mismatch repair£Û23£Ý. Additionally, 5-mCyt
may influence carcinogenesis via inhibition of DNA
repair,     leading     to     fixation     of    promutagenic
lesions[5,25]. However, the high percentage of muta-
tions at CpG sites can not be explained solely by the
presence of 5-mCyt, as the methylation patterns of
the p53 gene are tissue independent, suggesting that
tissue specific methylation does not contribute to the
different mutation patterns at CpG sites seen in
tumors[32]. This supports the contention that the ef-
fect of DNA methylation alterations may vary in
different tissues and in the genesis of different tu-
mor types.
         The  complex  nature  of  the  methylation  role  in
region of gene expression is illustrated by the insulin
growth factor type II receptor (Igf2r) gene. Both
hypomethylation  of  the  5’ flanking  region  and
methylation of a specific CpG site in an intron are
required for the occurrence of expression. The lat-
ter appears to be an imprinting signal, and hy-
pomethylation at this site may silence the gene even
if the 5’flanking region remains hypomethylated[33].
          The  epigenetic  properties  of  DNA  methylation
are heritable and unlike the mutagenic effects of 5-
mCyt which do not involve alterations of the prima-
ry DNA sequence. Methylation of cytosine residues
contained in CpG islands of certain genes has been
inversely correlated with gene activity, but it is still
unclear whether this methylation is actually respon-
sible for different activity states of a gene or is
merely the result of such changes. Methylation at a
CpG islands may lead to decreased gene expression
by a variety of mechanisms including disruption of
local chromatin structure, inhibition of transcrip-
tion  factor  DNA,  or  by  recruitment  of  proteins
which  interact  specifically  with  methylated  se-
quences indirectly preventing transcription factor
binding[5,34]. Increased methylation and hete-
rochromatization of CpG islands have been pro-
posed as a mechanism for silencing the expression of
non-essential genes during the establishment of im-
mortal cell lines.
CONCLUSION
The current literature provides a compelling basis
for suggesting that mutations arising secondarily to
deamination of 5-mCyt, C or both are an important
source of critical point mutations. Mutation, altered
gene expression, hypomethylation and hypermethy-
lation may be all related to carcinogenesis which are
not mutually exclusive. Hypomethylation, hyper-
methylation and mutations may be important based
on different situations. The examination of DNA
methylation status provides the potential to discover
alterations in gene expression, cell proliferation,
mutation, chromatin aberrations and inactivation/
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deletion of tumor suppressor genes in multifaceted
approach  that  fits  the  multistep  process  of
carcinogenesis. This notion can be supported by the
depiction of human colon carcinogenesis in which
roles for hypomethylation of DNA, mutation and
tumor suppressor gene inactivation are considered to
be relevant to the ultimate tumor formation[5,25].
There  is  a  need  to  address  the  functional  signifi-
cance of specific changes in methylation (e.g., how
the binding of transcating factors to specific genes is
affected by methylation), and changes in methyla-
tion that occur in target tissues prior to the appear-
ance of frank malignancies. The overall goal should
be an understanding of changes in methylation and
how they facilitate movement of cells through the
different stages of carcinogenesis. This can be ac-
complished by keeping in perspective the fact that
cancer is a disease of the whole entity, and thus
there is a need to focus, though not exclusively, on
in vivo studies.
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